Simplifikasi Terapi Insulin untuk Diabetes Tipe 2 Tidak Terkontrol: Pilihan yang Tersedia di Formularium Jaminan Kesehatan Nasional

Oleh :

dr.Eduward Thendiono, SpPD,FINASIM

Simplifikasi terapi insulin untuk tata laksana pasien dengan diabetes mellitus tipe 2 (DM tipe 2) yang tidak terkontrol perlu dilakukan dan didukung dengan ketersediaannya di formularium jaminan kesehatan nasional (JKN). Hal ini direkomendasikan agar mengurangi efek samping seperti hipoglikemia dan penambahan berat badan, serta meningkatkan cost-effectiveness dan angka kepatuhan pasien, sehingga komplikasi kardiovaskular akibat DM tipe 2 dapat ditekan.

Rekomendasi Kontrol Kadar Glukosa pada Diabetes Mellitus tipe 2

Rekomendasi Standards of Medical Care In Diabetes tahun 2022 oleh American Diabetes Association (ADA) untuk kontrol glikemik bagi pasien diabetes mellitus tipe 2 (DM tipe 2) yang tidak hamil menargetkan preprandial capillary plasma glucose di antara 80-130 mg/dL atau 4,4-7,2 mmol/L, peak postprandial capillary plasma glucose <180 mg/dL atau 10 mmol/L, dan HbA1c <7,0%.[1]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. American Diabetes Association Professional Practice Committee. 6. Glycemic targets: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Suppl. 1):S83–S96
2. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Suppl. 1):S125–S143
3. Atkin S, javed Z, Fulcher G. Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Ther Adv Chronic Dis 2015;6(6):375-388. Doi: 10.1177/2040622315608646.
4. Hinnen DA. Therapeutic options for the management of postprandial glucose in patients with type 2 diabetes on basal insulin.Clin Diabetes.2015;33(4):175-180. Doi:10.2337/diaclin.33.4.175
5. Ooi CP, Ting TH, Lye MS. Ultra long acting insulin versus long-acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev.2018.26:2018(7):CD011102.doi: 10.1002/14651858. CD 011102. pub2.
6. Dalal MR,Kazemi M, Ye F, Xie L. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization. Adv Ther.2017;34(9):2083-2092. Doi: 10.1007/s12325-017-0592-x.
7. Eberhard Standl, David R. Owen; New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?. Diabetes Care 1 August 2016; 39 (Supplement_2): S172–S179.https://doi.org/10.2337/dcS15-3011
8. Kalra S et al. Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care. Diabetes Ther 2018. 9:2185–2199 https://doi.org/10.1007/s13300-018-0521-2
9. Vora, J., Christensen, T., Rana, A. and Bain, S. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther 2014. 5:435–446.
10. Atkin S et al. Insulin degludec and insulin aspart: novel insulins for the management of diabetes melitus. Ther Adv Chronic Dis. 2015 6(6):375-388.doi: 10.1177/2040622315608646
11. Glastras SJ et al. The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from experience in Australia. J Clin. Med 2020 ,9,1091; doi:10.3390/jcm9041091
12. Fulcher GR, Akhtar A, Al-Jaser SJ, et al. Improved glycemic control in people with type 2 diabetes initiating or switching to IDegAsp from any-antihyperglycemic treatment in a real-world setting across six countries. Presented at the Australasian Diabetes Congress (ADC) virtual meeting, 11-13 August 2021.
13. Moreira RO, Cobas R, Coelho RCL. Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? Diabetol Metab Syndr (2018) 10:26 https://doi.org/10.1186/s13098-018-0327-4
14. Bala C, Cerghizan A, Mihai B-M, et al. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro). BMJ Open 2022;12:e060852. doi:10.1136/ bmjopen-2022-060852
15. Zenari L, Da Proto A, De Moliner L et al. Real-world Evaluation of Glycemic outcomes and Extra-glycemic parameters in diabetic patients treated with the combined formulation degludec-liraglutide (Ideglira). Diabetes Ther 12,197-209 (2021). https://doi.org/10.1007/s13300-020-00945-4.
16. Kementerian Kesehatan RI (Kemenkes). Daftar obat-E-fornas. Kemenkes 2022. http://e-fornas.binfar.kemkes.go.id
17. Pedoman Petunjuk Praktis Terapi Insulin Pada Pasien Diabetes Melitus 2021. Available at https://pbperkeni.or.id